MRE11 and Telangiectasia: Experimental studies have illustrated that TP53 mutations can accelerate tumorigenesis by interacting with the nuclease Mre11 and disrupting the Mre11–rad50–nbs1 complex, thereby inhibiting the activation of ataxia telangiectasia mutated.25